Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...

Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for ...

Reblozyl also has an edge on the entrenched Epogen/Procrit alternative with its convenience factor. The BMS drug is dosed every three weeks, compared with the ESA’s weekly administration.

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has ...

REBLOZYL ® is the first and only erythroid maturation agent approved for use in Canada MONTREAL, Sept. 29, 2020 /CNW/ - Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today ...

MONTREAL& CAMBRIDGE, Mass.---- Bristol Myers Squibb Canada and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL ® for the treatment of adult patients with red blood ...